Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Pr

– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation from pancreatic adenocarcinoma trial –– Median Progression-Free Survival was 1...

Related Keywords

Texas , United States , Denver , Colorado , Stevenc Katz , Sapna Patel , Trisalu Trinav , Exchange Commission , Society Of Immunotherapy , Nasdaq , Linkedin , Twitter , University Of Texas Md Anderson Cancer Center , Trisalus Life Sciences , Median Progression Free Survival , Disease Control Rate , Trisalus Life , Infusion System , Progression Free Survival , Chief Medical Officer , Pressure Enabled Regional Immuno Oncology , Pressure Enabled Drug Delivery , Pancreatic Retrograde Venous Infusion System , Private Securities Litigation Reform Act ,